Rick Doblin, Ph.D. Interview with New Scientist

Rick Doblin outlines the mission of the Multidisciplinary Association for Psychedelic Studies, known as MAPS, which functions as a non-profit pharmaceutical developer. The primary objective is to advance psychedelic substances through rigorous clinical trials to achieve FDA approval as prescription medications for therapeutic use. Specific attention is given to ongoing research concerning LSD, which is being studied for its potential in treating anxiety among terminally ill patients in Switzerland. Additionally, FDA approval has been secured for MDMA clinical trials at Harvard, specifically targeting treatment for cancer patients. Beyond these clinical efforts, MAPS maintains a commitment to public education, policy shifting, and medical access. This includes lobbying efforts in Washington, D.C., to challenge existing regulatory barriers and support the development of medical-grade production facilities.